OverviewSuggest Edit

Meridian Bioscience is a life science company which develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The Company offers testing platforms and technologies. These products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens.The Company also provides bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies.

TypePublic
Founded1977
HQCincinnati, US
Websitemeridianbioscience.com
Employee Ratings2.2

Latest Updates

Employees (est.) (Sept 2019)660(+13%)
Job Openings35
Revenue (FY, 2019)$201 M(-5%)
Share Price (Oct 2020)$18.1 (-7%)
Cybersecurity ratingBMore

Key People/Management at Meridian Bioscience

Bryan Baldasare

Bryan Baldasare

Executive Vice President and Chief Financial Officer
Melissa McCarey

Melissa McCarey

Vice President, Global Human Resources
Lourdes Weltzien

Lourdes Weltzien

Executive Vice President, Life Science
Jack Kenny

Jack Kenny

Chief Executive Officer
Show more

Meridian Bioscience Office Locations

Meridian Bioscience has offices in Cincinnati, Eveleigh, Braine-l'Alleud, Paris and in 4 other locations
Cincinnati, US (HQ)
3471 River Hills Dr
Eveleigh, AU
Suite G16A, NIC Building Australian Technology Park
Braine-l'Alleud, BE
2 Avenue du Japon
Paris, FR
34 Rue de Ponthieu
Luckenwalde, DE
3 Im Biotechnologiepark
Milano, IT
7 Via dell'Industria
Show all (8)

Meridian Bioscience Financials and Metrics

Meridian Bioscience Revenue

Embed Graph
View revenue for all periods
Meridian Bioscience's revenue was reported to be $201.01 m in FY, 2019
USD

Revenue (Q3, 2020)

84.8m

Gross profit (Q3, 2020)

55.9m

Gross profit margin (Q3, 2020), %

65.9%

Net income (Q3, 2020)

27.5m

EBIT (Q3, 2020)

34.7m

Market capitalization (16-Oct-2020)

774.7m

Closing stock price (16-Oct-2020)

18.1

Cash (30-Jun-2020)

63.4m

EV

816.8m
Meridian Bioscience's current market capitalization is $774.7 m.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

26.6m26.8m33.4m38.0m34.7m35.5m32.2m21.6m23.8m24.4m

Depreciation and Amortization

3.1m5.9m6.6m5.6m5.6m5.2m6.6m8.1m7.9m10.0m

Inventories

(1.1m)3.8m

Accounts Payable

4.1m(2.3m)
Quarterly
USDQ3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

6.4m6.0m13.3m20.1m6.6m16.2m24.8m8.5m18.7m28.9m7.4m17.7m26.6m7.9m18.0m27.1m8.9m18.0m26.7m6.3m15.6m15.8m6.3m11.6m18.4m8.1m15.2m20.3m2.8m12.2m39.7m

Depreciation and Amortization

845.0k1.7m2.5m903.0k1.8m2.7m815.0k1.7m2.5m1.4m2.8m4.2m1.4m2.7m3.9m1.3m2.5m4.7m2.0m4.1m6.1m2.1m4.1m6.1m2.1m4.2m6.8m2.9m5.9m9.4m

Inventories

(2.4m)(2.4m)(4.1m)(37.0k)832.0k(67.0k)(3.5m)(2.5m)(17.8m)

Accounts Payable

1.3m3.7m3.0m(4.1m)(1.3m)(1.7m)(664.0k)1.6m4.4m
USDQ3, 2010

Financial Leverage

1.1 x
Show all financial metrics

Meridian Bioscience Acquisitions / Subsidiaries

Company NameDateDeal Size
Exalenz BioscienceMay 01, 2020$49 m

Meridian Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Meridian Bioscience Online and Social Media Presence

Embed Graph

Meridian Bioscience News and Updates

Meridian Bioscience Launches a Complete Solution to Support Liquid Biopsy Cancer Diagnostics

CINCINNATI, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete solution improving the development of cancer diagnostic tests, allowing direct …

Meridian Bioscience to Participate in the 40th Annual William Blair Growth Stock Conference

CINCINNATI, May 29, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40th Annual William Blair Gr…

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an imp…

Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak

CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. The outbreak started on the C…

Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance

CINCINNATI, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2019.

Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019

CINCINNATI, July 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019 financial results Tuesday, July 30, 2019.
Show more

Meridian Bioscience Blogs

Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics

CINCINNATI , May 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience , Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics.  Jack Kenny remains Chief Executive Officer of Meridian, while passing responsibility of

Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products

CINCINNATI , May 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020 . Second Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $57.3 million , up 14% year-over-year Life Science segment

Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay

CINCINNATI , May 06, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use.  The

Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience

CINCINNATI , April 30, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID ®

Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply

CINCINNATI , April 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular

Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

CINCINNATI , March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays
Show more

Meridian Bioscience Frequently Asked Questions

  • When was Meridian Bioscience founded?

    Meridian Bioscience was founded in 1977.

  • Who are Meridian Bioscience key executives?

    Meridian Bioscience's key executives are Bryan Baldasare, Melissa McCarey and Lourdes Weltzien.

  • How many employees does Meridian Bioscience have?

    Meridian Bioscience has 660 employees.

  • What is Meridian Bioscience revenue?

    Latest Meridian Bioscience annual revenue is $201 m.

  • What is Meridian Bioscience revenue per employee?

    Latest Meridian Bioscience revenue per employee is $304.6 k.

  • Who are Meridian Bioscience competitors?

    Competitors of Meridian Bioscience include Varex Imaging, Cisbio and Access Biologicals.

  • Where is Meridian Bioscience headquarters?

    Meridian Bioscience headquarters is located at 3471 River Hills Dr, Cincinnati.

  • Where are Meridian Bioscience offices?

    Meridian Bioscience has offices in Cincinnati, Eveleigh, Braine-l'Alleud, Paris and in 4 other locations.

  • How many offices does Meridian Bioscience have?

    Meridian Bioscience has 8 offices.